Idexx Laboratories Stock Performance
| IDXX Stock | USD 459.86 3.80 0.82% |
IDEXX Laboratories has a performance score of 6 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.38, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IDEXX Laboratories' returns are expected to increase less than the market. However, during the bear market, the loss of holding IDEXX Laboratories is expected to be smaller as well. IDEXX Laboratories at this time retains a risk of 2.08%. Please check out IDEXX Laboratories downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if IDEXX Laboratories will be following its current trending patterns.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in IDEXX Laboratories are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, IDEXX Laboratories may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
Actual Historical Performance (%)
One Day Return (0.82) | Five Day Return 1.2 | Year To Date Return 12.48 | Ten Year Return 481.99 | All Time Return 97.2 K |
Last Split Factor 2:1 | Last Split Date 2015-06-16 |
1 | IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma | 01/23/2025 |
2 | IDEXX Laboratories, Inc. Q4 2024 Earnings Call Transcript | 02/04/2025 |
3 | Are Options Traders Betting on a Big Move in IDEXX Stock | 02/10/2025 |
4 | Empirical Finance LLC Sells 28 Shares of IDEXX Laboratories, Inc. | 02/11/2025 |
5 | IDEXX Laboratories Independent Director M. Szostak Sells 49 percent Of Holding | 02/12/2025 |
6 | Acquisition by George Fennell of 217 shares of IDEXX Laboratories at 459.76 subject to Rule 16b-3 | 02/13/2025 |
7 | IDEXX Laboratories Fell Due to Weakening of Clinical Visits by Patients | 02/14/2025 |
8 | Rule Breaker Investing Stock Stories, Vol. 10 Frosty Campfire, Fiery Stocks | 02/19/2025 |
9 | Impax Asset Management Group plc Has 3.53 Million Position in IDEXX Laboratories, Inc. | 02/25/2025 |
| Begin Period Cash Flow | 453.9 M |
IDEXX |
IDEXX Laboratories Relative Risk vs. Return Landscape
If you would invest 42,175 in IDEXX Laboratories on November 28, 2024 and sell it today you would earn a total of 3,811 from holding IDEXX Laboratories or generate 9.04% return on investment over 90 days. IDEXX Laboratories is currently generating 0.1699% in daily expected returns and assumes 2.0837% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than IDEXX, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IDEXX Laboratories Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IDEXX Laboratories' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IDEXX Laboratories, and traders can use it to determine the average amount a IDEXX Laboratories' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0816
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IDXX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.08 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average IDEXX Laboratories is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IDEXX Laboratories by adding it to a well-diversified portfolio.
IDEXX Laboratories Fundamentals Growth
IDEXX Stock prices reflect investors' perceptions of the future prospects and financial health of IDEXX Laboratories, and IDEXX Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IDEXX Stock performance.
| Return On Equity | 0.58 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 38.41 B | ||||
| Shares Outstanding | 81.33 M | ||||
| Price To Earning | 61.31 X | ||||
| Price To Book | 23.64 X | ||||
| Price To Sales | 9.60 X | ||||
| Revenue | 3.9 B | ||||
| Gross Profit | 2.38 B | ||||
| EBITDA | 1.13 B | ||||
| Net Income | 887.87 M | ||||
| Cash And Equivalents | 114.36 M | ||||
| Cash Per Share | 1.37 X | ||||
| Total Debt | 265.62 M | ||||
| Debt To Equity | 3.27 % | ||||
| Current Ratio | 0.89 X | ||||
| Book Value Per Share | 19.55 X | ||||
| Cash Flow From Operations | 929 M | ||||
| Earnings Per Share | 10.67 X | ||||
| Market Capitalization | 37.4 B | ||||
| Total Asset | 1.89 B | ||||
| Retained Earnings | 5.33 B | ||||
| Working Capital | 331.98 M | ||||
| Current Asset | 821.63 M | ||||
| Current Liabilities | 856.76 M | ||||
About IDEXX Laboratories Performance
Evaluating IDEXX Laboratories' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if IDEXX Laboratories has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IDEXX Laboratories has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 91.79 | 119.88 | |
| Return On Tangible Assets | 0.64 | 0.68 | |
| Return On Capital Employed | 1.37 | 1.43 | |
| Return On Assets | 0.47 | 0.49 | |
| Return On Equity | 0.56 | 0.58 |
Things to note about IDEXX Laboratories performance evaluation
Checking the ongoing alerts about IDEXX Laboratories for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IDEXX Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IDEXX Laboratories currently holds 265.62 M in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about IDEXX Laboratories' use of debt, we should always consider it together with its cash and equity. | |
| Over 93.0% of IDEXX Laboratories shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Impax Asset Management Group plc Has 3.53 Million Position in IDEXX Laboratories, Inc. |
- Analyzing IDEXX Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IDEXX Laboratories' stock is overvalued or undervalued compared to its peers.
- Examining IDEXX Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IDEXX Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IDEXX Laboratories' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IDEXX Laboratories' stock. These opinions can provide insight into IDEXX Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.